Supplementary Table 1. Baseline characteristics of included and excluded patients

Characteristics	Excluded (n=492)	Included (n=5,920)	*P*
Age (yr)	64.3 (56.9–72.0)	64.8 (57.0–71.4)	0.978
Female sex	166 (33.7)	2,004 (33.9)	0.960
Han ethnicity	476 (96.8)	5,806 (98.1)	0.045
BMI (kg/m^2)	24.2 (22.4–26.4)	24.5 (22.6–26.6)	0.313
Medical history			
Hypertension	345 (70.1)	4,385 (74.1)	0.056
Diabetes	146 (29.7)	1,896 (32.0)	0.282
Dyslipidemia	132 (26.8)	1,651 (27.9)	0.614
Previous ischemic stroke	105 (21.3)	1,245 (21.0)	0.871
Previous TIA	5 (1.02)	83 (1.4)	0.480
Coronary heart disease	50 (10.2)	508 (8.6)	0.232
Myocardial infarction	11 (2.2)	85 (1.4)	0.160
Peripheral artery disease	1 (0.2)	12 (0.2)	0.998
Current smoking	137 (27.9)	1,844 (31.2)	0.128
CYP2C19 LOF allele carriers			0.411
Intermediate metabolizers	391 (79.5)	4,610 (77.9)	
Poor metabolizers	101 (20.5)	1,310 (22.1)	
Time to randomization (h)	13.4 (8.8–20.2)	14.0 (9.0–20.5)	0.594
Qualifying event			0.184
Ischemic stroke	407 (82.7)	4,751 (80.3)	
TIA	85 (17.3)	1,169 (19.8)	
NIHSS score in patients with qualifying ischemic stroke*	2 (1–3)	2 (1–3)	<0.001
ABCD^2 score in patients with qualifying TIA†	5 (4–5)	4 (4–5)	0.323
Previous lipid-lowering therapy‡	36 (7.3)	463 (7.8)	0.689
HDL-C (mmol/L)	1.10 (0.90–1.30)	1.11 (1.00–1.30)	0.102
Decreased renal function§	166 (33.7)	1,865 (31.5)	0.306
Outcomes			
Stroke within 90 days	30 (6.1)	404 (6.8)	0.538
Composite vascular events within 90 days‖	36 (7.3)	486 (8.2)	0.487
Severe or moderate bleeding within 90 days¶	1 (0.2)	19 (0.3)	0.653

Values are presented as median (interquartile range) or n (%).
BMI, body mass index; TIA, transient ischemic attack; LOF, loss-of-function; NIHSS, National Institutes of Health Stroke Scale; ABCD^2, age, blood pressure, clinical features, duration of symptoms, diabetes; HDL-C, high-density lipoprotein cholesterol.
*NIHSS scores range from 0 to 42, with higher scores indicating more severe stroke; †ABCD^2 score assesses the risk of stroke on the basis of age, blood pressure, clinical features, duration of TIA, and presence or absence of diabetes, with scores ranging from 0 to 7 and higher scores indicating greater risk; ‡Medication within 1 month before symptom onset; §Decreased renal function was defined as estimated glomerular filtration rate ≤90 mL/min/1.73 m^2 according to the NKF-KDOQI (National Kidney Foundation Kidney Disease Outcomes Quality Initiative) guidelines; ‖Composite vascular events include ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction, and vascular death; ¶Severe or moderate bleeding was defined according to Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) criteria.